BASEL, Switzerland (Reuters) – Novartis plans to test a novel pricing model with some customers when it launches its keenly awaited new heart failure drug Entresto, the Swiss company’s head of pharmaceuticals said on Tuesday.
Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. As a result, it is widely expected to generate billions of dollars in annual sales.
BASEL, Switzerland (Reuters) – Swiss drugmaker Novartis AG (NOVN.VX: Quote, Profile, Research, Stock Buzz) boosted its presence in pain management on Monday by agreeing to buy U.S.-Australian biotech firm Spinifex Pharmaceuticals, the companies said in separate statements on Monday.
Spinifex said Novartis was paying $200 million upfront and Spinifex shareholders could get further payments based on clinical development and regulatory milestones. The transaction is expected to close in the second half of this year, pending regulatory approval.
BASEL, Switzerland (Reuters) – Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action.
“In the worst-case scenario of ‘Grexit’, we believe the
integrity of the medicines supply chain may be in jeopardy, which would create a risk to public health,” the industry’s trade association said in a letter to the European Commission.
BASEL, Switzerland, June 29 (Reuters) – Novartis
is increasingly confident about the potential of its new
injectable drug Cosentyx, as fresh clinical data confirms its
long-term benefits in treating psoriatic arthritis.
Cosentyx was approved by the U.S. Food and Drug
Administration in January for treating the painful skin
condition plaque psoriasis, but the company also has high hopes
for the product in related conditions.
LONDON, June 25 (Reuters) – Scientists have identified a key
gene used by poppies to make morphine, paving the way for better
methods of producing the medically important drug, potentially
without the need for cultivating poppy fields.
The latest finding follows recent success in engineering
brewer’s yeast to synthesise opiates such as morphine and
codeine from a common sugar, boosting the prospect of
“home-brew” drug supply.
LONDON (Reuters) – Eli Lilly has won a patent case in the Court of Appeal in London over its blockbuster Alimta lung cancer drug, boosting prospects for future sales and dealing a blow to generic challenger Actavis, now renamed Allergan.
Alimta generated worldwide sales of $2.79 billion for Lilly last year, making the medicine its biggest-selling product. Shares in the U.S. drugmaker jumped 5 percent on Thursday.
LONDON, June 25 (Reuters) – A genetically engineered wheat
that gives off a special smell designed to repel aphids has
flopped in field-scale tests, underscoring the difficulty of
harnessing the controversial technology.
Scientists said the result was disappointing but they aim to
amend the process to do better in future, believing that genetic
modification (GM) offers a way to develop resilient crops that
don’t need to be sprayed with pesticides.
LONDON (Reuters) – Eli Lilly has won a patent case
in the Court of Appeal in London over its blockbuster Alimta
lung cancer drug, boosting prospects for future sales and
dealing a blow to generic challenger Actavis.
Alimta generated worldwide sales of $2.79 billion for Lilly
last year, making the medicine its biggest-selling product.
LONDON (Reuters) – AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.
His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved on to become CEO of privately owned cancer drug firm Syndax.
LONDON, June 17 (Reuters) – Scientists have discovered a new
anti-malarial compound that could treat patients with a single
$1 dose, including those with strains of the mosquito-borne
disease that are resistant to current drugs.
Although it is still years from reaching the market, results
from tests conducted on human blood in the laboratory and in
live mice suggest it is highly potent, researchers reported in
the journal Nature on Wednesday.